OncoMatch/Clinical Trials/NCT06888843
Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.
Is NCT06888843 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Capecitabine and Oxaliplatin for colorectal cancer.
Treatment: Capecitabine · Oxaliplatin — All patients with locally advanced colorectal cancer after radical surgical intervention who have not previously received systemic antitumor treatment will be randomized into two groups receiving fluoropyrimidines in mono-regimen and in combination with oxaliplatin. Main objectives: * to compare the 3-year disease-free survival and 5-year overall survival rates in the two groups. * to identify, through a comprehensive geriatric assessment among elderly patients, the groups that benefit most from adjuvant chemotherapy. Patients will be treated until progression of the process is detected or the maximum effect of therapy is reached (the longest duration of treatment is 6 months).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: DPYD dihydropyrimidine dehydrogenase deficiency
Confirmed dihydropyrimidine dehydrogenase deficiency in blood by PCR (alteration of alleles c.[190511G > A], c.[1679T >G],[2846A > T], [1129-5923C >G], [c.1236 G>A(HapB3)])
Disease stage
Required: Stage III
Excluded: Stage I, II, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery — primary colorectal tumor
Underwent radical surgical intervention for primary colorectal tumor
Cannot have received: systemic therapy
Having previously received any systemic therapy for CRC
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate kidney function
Liver function
Adequate liver function
Adequate liver, kidney and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06888843 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with DPYD alterations eligible?
No. DPYD dihydropyrimidine dehydrogenase deficiency is an exclusion criterion.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 90 years or younger and at least 70 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages